2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

,

doi:10.17998/jlc.2022.11.07

Cited by 42 publications

(38 citation statements)

References 1,027 publications

(1,082 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCC was defined as a case in which suspicious lesions were found through USG and subsequent imaging tests, such as CT or MRI, confirmed the findings according to the Korean Liver Cancer Association-National Cancer Center practice guidelines. 7…”

Section: Data Collection and Classification Of Hccmentioning

confidence: 99%

Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study

Yoo¹,

Kim²,

Kim

et al. 2023

JLC

View full text Add to dashboard Cite

Background/Aim: Abdominal ultrasonography (USG) is recommended as a surveillance test for high-risk groups for hepatocellular carcinoma (HCC). This study aimed to analyze the current status of the national cancer surveillance program for HCC in South Korea and investigate the effects of patient-, physician-, and machine-related factors on HCC detection sensitivity.Methods: This multicenter retrospective cohort study collected surveillance USG data from the high-risk group for HCC (liver cirrhosis or chronic hepatitis B or C >40 years of age) at eight South Korean tertiary hospitals in 2017.Results: In 2017, 45 experienced hepatologists or radiologists performed 8,512 USG examinations. The physicians had a mean 15.0±8.3 years of experience; more hepatologists (61.4%) than radiologists (38.6%) participated. Each USG scan took a mean 12.2±3.4 minutes. The HCC detection rate by surveillance USG was 0.3% (n=23). Over 27 months of follow-up, an additional 135 patients (0.7%) developed new HCC. The patients were classified into three groups based on timing of HCC diagnosis since the 1st surveillance USG, and no significant intergroup difference in HCC characteristics was noted. HCC detection was significantly associated with patient-related factors, such as old age and advanced fibrosis, but not with physician- or machine-related factors.Conclusions: This is the first study of the current status of USG as a surveillance method for HCC at tertiary hospitals in South Korea. It is necessary to develop quality indicators and quality assessment procedures for USG to improve the detection rate of HCC.

show abstract

Section: Data Collection and Classification Of Hccmentioning

confidence: 99%

Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study

Yoo¹,

Kim²,

Kim

et al. 2023

JLC

View full text Add to dashboard Cite

show abstract

“…However, the majority of patients present with advanced HCC and face a grim prognosis. 4 Multikinase inhibitors, such as sorafenib and lenvatinib, have gained approval as first-line systemic treatments for unresectable advanced HCC, demonstrating improved survival rates compared with placebos. 5 - 7 However, these gains in survival are modest, considering the multiple adverse events (AEs).…”

Section: Introductionmentioning

confidence: 99%

Complications of immunotherapy in advanced hepatocellular carcinoma

Song,

Yoo,

Kim

et al. 2024

JLC

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) are highly effective in cancer treatment. However, the risks associated with the treatment must be carefully balanced against the therapeutic benefits. Immune-related adverse events (irAEs) are generally unpredictable and may persist over an extended period. In this review, we analyzed common irAEs reported in highly cited original articles and systematic reviews. The prevalent adverse reactions include fatigue, pyrexia, rash, pruritus, diarrhea, decreased appetite, nausea, abdominal pain, constipation, hepatitis, and hypothyroidism. Therefore, it is crucial to conduct evaluations not only of gastrointestinal organs but also of cardiac, neurologic, endocrine (including the frequently affected thyroid), and ophthalmic systems before commencing ICIs. This review further explores commonly reported types of irAEs, specific irAEs associated with each ICI agent, rare yet potentially fatal irAEs, and available treatment options for managing them.

show abstract

“…Sorafenib can be used to prolong the overall survival (OS) and time-to-progression. 4 , 5 Recently, a combination of atezolizumab and bevacizumab has shown promise in clinical trials and has the potential to improve outcomes in these patients. 6 Individualized treatment plans and multidisciplinary approaches are crucial for managing HCC with PVTT.…”

Section: Introductionmentioning

confidence: 99%

Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis

Lim,

Kim,

Rhu

et al. 2024

JLC

View full text Add to dashboard Cite

Background/Aim: Hepatocellular carcinoma (HCC) tumor thrombi located in the first branch of the portal vein (Vp3) or in the main portal trunk (Vp4) are associated with poor prognosis. This study aimed to investigate the clinicopathological characteristics and risk factors for HCC recurrence and mortality following liver resection (LR) in patients with Vp3 or Vp4 HCC.Methods: The study included 64 patients who underwent LR for HCC with Vp3 or Vp4 portal vein tumor thrombosis (PVTT).Results: Fifty-eight patients (90.6%) had Vp3 PVTT, whereas the remaining six patients exhibited Vp4 PVTT. The median tumor size measured 8 cm, with approximately 36% of patients presented with multiple tumors. Fifty-four patients (84.4%) underwent open LR, whereas 10 patients underwent laparoscopic LR. In the Vp4 cases, combined LR and tumor thrombectomy were performed. The 3-year cumulative disease-free survival rate was 42.8% for the Vp3 group and 22.2% for the Vp4 group. The overall survival (OS) rate at 3 years was 47.9% for the Vp3 group and 60.0% for the Vp4 group. Intrahepatic metastasis has been identified as an important contributor to HCC recurrence. High hemoglobin levels are associated with high mortality.Conclusion: LR is a safe and effective treatment modality for selected patients with Vp3 or Vp4 HCC PVTT. This suggests that LR is a viable option for these patients, with favorable outcomes in terms of OS.

show abstract

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited by 42 publications

References 1,027 publications

Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study

Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study

Complications of immunotherapy in advanced hepatocellular carcinoma

Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis

Contact Info

Product

Resources

About